70 related articles for article (PubMed ID: 19424994)
1. Bayesian methods in cost-effectiveness studies: objectivity, computation and other relevant aspects.
Armero C; García-Donato G; López-Quílez A
Health Econ; 2010 Jun; 19(6):629-43. PubMed ID: 19424994
[TBL] [Abstract][Full Text] [Related]
2. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
Spiegelhalter DJ; Best NG
Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
4. Large-sample Bayesian posterior distributions for probabilistic sensitivity analysis.
Hazen GB; Huang M
Med Decis Making; 2006; 26(5):512-34. PubMed ID: 16997928
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
6. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
[TBL] [Abstract][Full Text] [Related]
7. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.
Lambert PC; Sutton AJ; Burton PR; Abrams KR; Jones DR
Stat Med; 2005 Aug; 24(15):2401-28. PubMed ID: 16015676
[TBL] [Abstract][Full Text] [Related]
8. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation.
Vanness DJ; Kim WR
Health Econ; 2002 Sep; 11(6):551-66. PubMed ID: 12203757
[TBL] [Abstract][Full Text] [Related]
9. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
Cox ER; Motheral B; Mager D
Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
[TBL] [Abstract][Full Text] [Related]
10. Bayesian analysis of non-homogeneous Markov chains: application to mental health data.
Sung M; Soyer R; Nhan N
Stat Med; 2007 Jul; 26(15):3000-17. PubMed ID: 17173342
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian model averaging approach for cost-effectiveness analyses.
Conigliani C; Tancredi A
Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
[TBL] [Abstract][Full Text] [Related]
12. Bayesian cost-effectiveness analysis from clinical trial data.
O'Hagan A; Stevens JW; Montmartin J
Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
[TBL] [Abstract][Full Text] [Related]
13. Large hierarchical Bayesian analysis of multivariate survival data.
Gustafson P
Biometrics; 1997 Mar; 53(1):230-42. PubMed ID: 9147593
[TBL] [Abstract][Full Text] [Related]
14. Bayesian estimation of cost-effectiveness from censored data.
Heitjan DF; Kim CY; Li H
Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
[TBL] [Abstract][Full Text] [Related]
15. Exploring heterogeneity in tumour data using Markov chain Monte Carlo.
de Gunst MC; Dewanji A; Luebeck EG
Stat Med; 2003 May; 22(10):1691-707. PubMed ID: 12720305
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian mixture model for partitioning gene expression data.
Zhou C; Wakefield J
Biometrics; 2006 Jun; 62(2):515-25. PubMed ID: 16918916
[TBL] [Abstract][Full Text] [Related]
17. Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement.
Dong H; Buxton M
Int J Technol Assess Health Care; 2006; 22(2):191-202. PubMed ID: 16571195
[TBL] [Abstract][Full Text] [Related]
18. Exploring fast computational strategies for probabilistic phylogenetic analysis.
Rodrigue N; Philippe H; Lartillot N
Syst Biol; 2007 Oct; 56(5):711-26. PubMed ID: 17849326
[TBL] [Abstract][Full Text] [Related]
19. The utility of prior information and stratification for parameter estimation with two screening tests but no gold standard.
Gustafson P
Stat Med; 2005 Apr; 24(8):1203-17. PubMed ID: 15558709
[TBL] [Abstract][Full Text] [Related]
20. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
